Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

Rhythm initiates phase IIb clinical trial of relamorelin for diabetic gastroparesis

Thursday, April 9, 2015

Rhythm, a biopharmaceutical company, and Actavis, a global pharmaceutical company, have initiated a phase IIb clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm’s ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal (GI) motility. Actavis has an exclusive option to acquire Rhythm’s wholly owned subsidiary, Rhythm Pharmaceuticals, upon the completion of the phase IIb study.

[Read More]

Actavis signs option to acquire Rhythm subsidiary

Thursday, October 23, 2014

Actavis, a Dublin, Ireland-based global specialty pharmaceutical company, has been granted an exclusive option to acquire Rhythm subsidiary Rhythm Health, a Boston, Mass.-based biopharmaceutical company developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.

[Read More]

Rhythm initiates phase II trial of RM-131 for chronic constipation

Friday, April 19, 2013

Rhythm, a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases, initiated an additional phase II trial of RM-131, the company’s novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

[Read More]

Rhythm names chief scientific officer

Wednesday, November 30, 2011

Rhythm has named Lex Van der Ploeg, PhD, chief scientific officer. Van der Ploeg brings to Rhythm more than 25 years of drug development experience in obesity, metabolic diseases, and other therapeutic areas.

[Read More]